Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 214 participants.

Also called NCT05504226

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 214 participants (enrolled count) (from the registry)
Sponsor
  • Handok Inc. Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05504226
Other papers using this trial's data
  • A 52-Week Efficacy and Safety Study of Teneligliptin, as an Add-On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial (TERA305 Study) Diabetes, obesity & metabolism, 2026-12 DOI, PubMed 42832816, PMC13730988 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05504226. Randomized; quadruple masking; primary purpose treatment. Start 2022-10-12 (actual); primary completion 2023-11-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin
Acronym
TERA 305
Intervention (Drug)
Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet
Intervention (Drug)
Teneligliptin Placebo Oral Tablet
Lead sponsor
Handok Inc. (class: industry)

Record details

Record id
cardio:ct-nct05504226
Content hash
123689da1f086c2fc1e9e75496d5f15ff05b47d3b46edd763bf9eb5dc46eaa6f